Jazz Pharmaceuticals Plc is a specialty biopharmaceutical company that identifies, develops, and commercializes medicines with a focus on narcolepsy, cancer, pain, and psychiatry. The company has a diverse portfolio of marketed medicines, including leading therapies for sleep disorders, epilepsy, and a growing portfolio of cancer treatments. It is dedicated to developing life-changing medicines for people with serious diseases, often with limited or no therapeutic options, to improve their quality of life.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. 

Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has a significant corporate presence in Palo Alto, CA and  Philadelphia, PA and in England in London, Oxford and Cambridge, with manufacturing facilities in Ireland, England and Italy. We maintain a highly collaborative culture where employees focus on how they can be successful and accomplish positive results by exemplifying the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. 

Together, we are experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to patients with critical unmet needs. 

Please see our website at www.jazzpharma.com for more information. For information on recruitment, please visit https://careers.jazzpharma.com/. For guidelines on engaging with Jazz on social media, please visit https://bit.ly/2OaMOuq. 


Kingsbridge Capital

Longitude Capital

Thoma Cressey Equity Partners

Versant Ventures

EGS Healthcare Capital Partners

Golden Gate Capital

Beecken Petty O'Keefe & Company

Prospect Venture Partners

Adams Street Partners

Lehman Brothers

Jazz Pharmaceuticals

Today, and every day, we remain committed to breaking down the stigma often felt by the #epilepsy community. By dispelling misconceptions and sharing the facts, we hope to help shift the conversation and build a broader, better understanding of epilepsy and seizures in support of those living with the condition.

Leading up to International #EpilepsyDay, Jazz colleagues from around the world participated in the INTERNATIONAL BUREAU FOR EPILEPSY #50MillionSteps for Epilepsy campaign, contributing a total of 115,124,213 steps to help put an end to #EpilepsyStigma.

Thank you to IBE for orchestrating this impactful effort and sending a powerful message of support and allyship to the global epilepsy community

While not everyone diagnosed with #biliarytractcancer (BTC) will have HER2-positivity, testing for HER2 is an important step for determining the appropriate treatment plan.

This #Cholangiocarcinoma Awareness Month, learn more about HER2 protein expression in BTC with our fact sheet: https://bit.ly/49pEufd

Today, along with Redx Pharma, we announced that the companies have signed a definitive agreement under which Jazz will acquire Redx's KRAS (Kirsten rat sarcoma virus) inhibitor program. Jazz and Redx will collaborate to advance candidates through IND-enabling studies; Jazz will be responsible for all clinical development, regulatory, manufacturing and commercialization activities. This transaction further expands our early-stage #oncology pipeline, and we are excited to explore novel approaches to improving treatment options for #cancer patients. https://lnkd.in/ehN98Pdt

#WorldCancerDay demonstrates the power of collaboration in the effort to reduce the global impact of cancer and #CloseTheCareGap for the millions of people impacted worldwide.  
 
Our commitment to delivering new value to patients starts with listening to their needs and garnering insights from physicians, care teams, advocacy groups and researchers in the oncology community so we can better develop new therapeutic standards of care. Learn how we are pioneering new pathways in oncology to help redefine what’s possible for patients facing unmet needs: https://bit.ly/3OuKrPQ


It is estimated that there will be 28 million new cases of cancer diagnosed worldwide each year by 2040*. This #WorldCancerDay, we are recognizing both the global progress that has been made to #ClosetheCareGap and the work that still remains to provide all patients with the support they need to live longer, healthier lives.  
  
Kelvin Tan, SVP and Chief Medical Officer, reflects on our pioneering research in #oncology and our commitment to helping advance the standard of cancer care for patients around the world. 
 
*Source: Cancer Research UK 


Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

COM:JAZZPHARMA

Cisco Systems Inc

Last Close

115.60

30/08 20:00

Market Cap

6.45B

Beta: -

Volume Today

330.50K

Avg: -

Analysis Not Available